Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO)’s stock price reached a new 52-week low on Thursday . The company traded as low as C$0.39 and last traded at C$0.36, with a volume of 34846 shares. The stock had previously closed at C$0.38.
Aptose Biosciences Stock Down 20.6 %
The company has a current ratio of 0.80, a quick ratio of 5.41 and a debt-to-equity ratio of 670.80. The company has a market capitalization of C$4.89 million, a P/E ratio of -0.05 and a beta of 1.36. The firm’s 50 day moving average price is C$0.51 and its two-hundred day moving average price is C$0.84.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
- Five stocks we like better than Aptose Biosciences
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- How Investors Can Find the Best Cheap Dividend Stocks
- MarketBeat Week in Review – 11/18 – 11/22
- Top Stocks Investing in 5G Technology
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
